Financial News

Financial Report: Pfizer

Biopharma revenues were $9.8 billion, up 6% operationally, primarily driven by Vyndaqel.

By: Contract Pharma

Contract Pharma Staff

Pfizer 2Q Revenues: $11.8 billion (-11%) 2Q Earnings: $3.4 billion (-32%)   YTD Revenues: $23.8 billion (-10%) YTD Earnings: $6.8 billion (-24%) Comments: Beginning in 2020, Upjohn began managing Pfizer’s Meridian subsidiary, the manufacturer of EpiPen and other auto-injector products, and a pre-existing strategic collaboration between Pfizer and Mylan for generic drugs in Japan. Acquisitions and other business development activities completed in 2019 and in the first half of...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters